Home Lung Monitoring for People with Rheumatic Disease-Related Lung Disease
Tests home lung checks against hospital visits in adults with rheumatic lung disease.
Plain-language title generated from the registry record
Registry title: Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
Key facts
- Where
- Oslo, NorwaySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a rheumatic disease and interstitial lung disease (lung scarring). It tests home lung-function checks against usual hospital visits.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A rheumatic disease (systemic sclerosis, rheumatoid arthritis, inflammatory muscle disease, mixed connective tissue disease or Sjøgren's disease) plus interstitial lung disease seen on a high resolution CT scan at least 1 year before joining.
- Earlier treatment
- Must have been on stable standard treatment for the 6 months before joining.
Main reasons for not taking part
- Severe heart failure (ejection fraction below 30%)
- Severe kidney failure (eGFR below 30 mL/min)
- End-stage lung disease or other severe lung disease such as COPD or emphysema
- Active cancer treatment or cancer that cannot be cured
- Prednisolone 20 mg/day or more at inclusion
Read by machine on 12 November 2026.
Where in Norway
- Oslo University HospitalOslo, NorwayContact: Anna-Maria Hoffmann-Vold, Prof DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT06732674
- Record updated
- 19 December 2024
- Original description
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.Read full original descriptionShow less
A 54-week, Multi-centre, 2-arm, Randomised Controlled Trial to Assess Home Monitoring for Lung Function and Patient Reported Outcome Measurements Vs. Usual Care in RheuMatic Disease-associated Interstitial Lung Disease: the RMD-mILDer Trial
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
It is planned as a 2 arm 54 week multi-centre randomised controlled trial to assess outcome of home monitoring with bi-weekly serial forced vital capacity- and patient reported outcome-measurements compared to standard of care with fixed-interval hospital visits in adult patients with rheumatic disease associated interstitial lung diseases.
Inclusion: Systemic rheumatic disease (Systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies including antisynthetasis syndromes (IIM), mixed connective tissue disease (MCTD) or Sjøgrens disease (SjD)) classifiable by disease-specific classification criteria; Diagnosed interstitial lung disease (ILD) on high resolution computed tomography (HRCT) ≥ 1 year prior to randomization, not explained by other diseases or exposures; On stable standard of care treatment 6 months prior to randomization; Participants must be able to understand and follow trial procedures including completion of questionnaires regarding Patient Reported Outcome measures; Participants must have access to the internet, and experience in using smartphones or other electronic devices with internet access; Signed informed consent form.
Exclusion: Significant pulmonary hypertension defined by the following: Previous clinical or echocardiographic evidence of significant right heart failure OR history of right heart catheterization showing a cardiac index </= 2 L/min/m2 OR pulmonary hypertension requiring therapy with epoprostenol/treprostinil; End stage lung disease with forced vital capacity (FVC) < 50% and/or diffusion capacity for carbon monoxide (DLCO) < 40% or coexisting severe other lung diseases (e.g. chronic obstructive pulmonary disease, emphysema); Active treatment for cancer or non-curable cancer; Severe heart failure with ejection fraction (EF) < 30%; Chronic renal failure G4 or more (defined by KDIGO) with glomerular filtration rate (eGFR) < 30 mL/min using Cockroft-Gault formula; Airway obstruction (pre-bronchodilator FEV1/FVC < 0.7) (FEV1 is defined as forced expiratory volume in 1 sec); In the opinion of the investigator, other clinically significant pulmonary abnormalities; Relative contraindications to performing spirometry, as specified in ATS/ERS guidelines; Ongoing Prednisolone ≥ 20 mg/day at inclusion; Unable to speak, write and read Norwegian, German or Romanian in the respective country of inclusion; Unable to perform good quality measurements of FVC on the home-device comparable to results on an in-hospital device, after training; Pregnancy or planned pregnancy.